Abstract:Background: Ensuring the quality and safety of the pharmaceutical supply chain is a key policy focus vital to protecting the public from harmful or potentially harmful medications. Although the Food and Drug Administration (FDA) reports the number of recalled products per fiscal year and categorizes recalls based on product type and recall classification, these reports do not distinguish between manufactured and compounded products. Objectives: This research aims to categorize drug recalls based on the reason for recall and then to compare this reason between manufacturers and compounders. Methods: All publicly available drug recall data were downloaded from the FDA Data Dashboard website on January 24, 2021. Two reviewers independently categorized the recalling firm, distribution pattern, and reason for recall, and a third reviewer resolved all conflicts. Descriptive statistics were reported for recall event classification, distribution, and recall reason for the full sample. Chi-square test of independence was used to assess categorical variables by facility type (manufacturer or compounder) as well as by event classification (class I, II, or III). A subgroup analysis was performed focusing on class I level recalls only, representing the most serious recall, and similar statistical procedures were performed. Results: From June 8, 2012, to January 24, 2021, there were 12,343 drug products recalled; 6771 were from a manufacturer, and 5572 were from a compounder. Most recalls from both compounders and manufacturers were class II recalls with products being distributed to multiple states. Sterility assurance was the predominant reason for recall among compounders, whereas product quality was the most frequent recall reason for manufacturers. There were statistically significant differences in class I recalls between compounders and manufacturers and recall reason compared across recall classification. Conclusion: There was a statistically significant difference in the reason for a drug to be recalled, the distribution level, and the product class for manufactured and compounded products.

A review and analysis of product recall for pharmaceutical drug product

Drug recall: An incubus for pharmaceutical companies and most serious drug recall of history

Drug Recalls: Trend analysis of Recalls by Indian Pharmaceutical Industry during the period 2013-2023

A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023

Ensuring Product Safety: A Comprehensive Retrospective Study of USFDA Drug Recalls (2019–2023)

An Analytic Investigation of the Drug Formulation-Based Recalls in the USA: See More Beyond the Literal

A Comprehensive Review on Assessment and Key Control Strategies for Impurities in Drug Development with a Special Emphasis on Post-marketing Surveillance

Categorization and comparisons of drug recalls for manufacturers and compounders

Drug Recall Monitoring and Trend Analysis: A Multidimensional Study

A Comprehensive Analysis of Class I Medical Device Recalls: Unveiling Patterns, Causes and Global Impacts

Data Analysis and Comparative Study on Drug Recall in China And America

Development of Predictive Statistical Model for Gaining Valuable Insights in Pharmaceutical Product Recalls

A four-year assessment of the characteristics of Rwandan FDA drug recalls

Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare

The Identification of Quality Risk Factors for Non-biological Complex Drugs and Epilepsy Drugs Using Statistical Analysis of Formulation-Based Recalls in the USA

Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality

Impact of Quality by Design Development on the Review Period of New Drug Approval and Product Quality in Japan

Impact of Drug Recalls on Patients in The Netherlands: A 5‐Year Retrospective Data Analysis

Lesson Learnt from Recall of Valsartan and Other Angiotensin II Receptor Blocker Drugs Containing NDMA and NDEA Impurities

Factors to Consider in Developing Individual Pharmaceutical Product Quality Risk Profiles Useful to Government Procurement Agencies

Indian Pharmaceutical Industries Current Status and Togetherness to Overcome Speed Breakers in Term of Quality Issues to make India as a Global Pharma Destination